Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration
Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
BACKGROUND The microtubule-associated protein tau has been implicated in the
pathogenesis of Alzheimer's disease and a range of other neurodegenerative disorders …
pathogenesis of Alzheimer's disease and a range of other neurodegenerative disorders …
A multicentre validation study of the diagnostic value of plasma neurofilament light
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum
Tau phosphorylated at threonine 181 (p-tau181) measured in blood plasma has recently
been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer's …
been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer's …
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Background Increasing evidence supports the use of plasma biomarkers of
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …
Alzheimer disease
DS Knopman, H Amieva, RC Petersen… - Nature reviews Disease …, 2021 - nature.com
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …